SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, ...

QuidelOrtho Corporation recently expanded its QUICKVUE portfolio with the launch of the QUICKVUE Influenza + SARS Test, a rapid, CLIA-waived immunoassay for professional use that delivers simultaneous ...

The Food and Drug Administration says Abbott's BinaxNOW test and Quidel's QuickVue can be sold without a prescription. FDA Authorizes 2 Rapid, At-Home Coronavirus Tests Imagine waking up, brushing ...

Select independently determines what we cover and recommend. When you buy through our links, we may earn a commission. Learn more. Gone are the days of visiting a doctor’s office to determine whether ...

WASHINGTON - The U.S. Food and Drug Administration has granted emergency use authorization for another COVID-19 at-home test. The agency approved the Quidel QuickVue At-Home COVID-19 Test, allowing ...

Last week, QuidelOrtho Corporation QDEL announced the availability of QUICKVUE Influenza + SARS Test. The CLIA-waived, 510(k)–cleared rapid, easy-to-use immunoassay is the latest addition to the ...

QuidelOrtho (QDEL) is expanding its QUICKVUE portfolio with the QUICKVUE Influenza + SARS Test, a CLIA-waived, 510(k)-cleared rapid, easy-to-use immunoassay designed for professional use in physician ...

Quidel plans initial release to professional and point-of-care segments with a goal of expansion to serve telemedicine and home markets Sofia Q is the latest product in Quidel’s best-selling Sofia ...